Ernexa Therapeutics (ERNAW) EBT Margin (2010 - 2024)
Ernexa Therapeutics' (ERNAW) quarterly EBT Margin came in at 204110.53% in Q4 2024, up 21667583.0% YoY from N/an in Q1 2024, and up 3838.03% on a QoQ basis from 5460.37% in Q3 2024.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) EBT Margin (2010 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 13 years of EBT Margin data on file, last reported at 204110.53% in Q4 2024.
- Quarterly EBT Margin rose 21667583.0% year-over-year to 204110.53% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 3.33% (up 2167433.0% YoY) and the FY2024 annual result came in at 3.33%, up 2167433.0% from the prior year.
- EBT Margin climbed to 204110.53% in Q4 2024, from 5460.37% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 204110.53% in Q4 2024 to a low of 14134.04% in Q1 2024.
- A 3-year average of 16607.28% and a median of 5460.37% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2020 — EBT Margin sank 9431 bps — and 2024, when it soared 21667583 bps.
- Tracing ERNAW's EBT Margin over 3 years: stood at 403.83% in 2020, then sank by 3212 bps to 12565.31% in 2023, then soared by 1724 bps to 204110.53% in 2024.
- The last three EBT Margin figures came in at 204110.53% (Q4 2024), 5460.37% (Q3 2024), and 11757.45% (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -30,357.89% |
| Sep 30, 2024 | -5,460.37% |
| Jun 30, 2024 | -11,757.45% |
| Mar 31, 2024 | -14,134.04% |
| Dec 31, 2023 | -12,565.31% |
| Sep 30, 2023 | -10,978.43% |
| Dec 31, 2020 | -216.68% |
| Sep 30, 2020 | -101.56% |
| Mar 31, 2020 | -51.67% |
| Dec 31, 2019 | -25.08% |
| Sep 30, 2019 | -7.25% |
| Jun 30, 2019 | -1.72% |
| Mar 31, 2019 | -6.25% |
| Dec 31, 2018 | -0.81% |
| Sep 30, 2018 | 3.86% |
| Jun 30, 2018 | -1.77% |
| Mar 31, 2018 | -7.06% |
| Dec 31, 2017 | -11.22% |
| Sep 30, 2017 | -3.37% |
| Jun 30, 2017 | -2.85% |